Search Results for keywords:"Drug Enforcement Administration"

The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have decided to delay the start date for two rules about using telemedicine to prescribe certain medications to December 31, 2025. These rules include the "Expansion of Buprenorphine Treatment via Telemedicine Encounter," which allows practitioners to prescribe medications for opioid use disorder, and "Continuity of Care via Telemedicine for Veterans Affairs Patients," which permits Veterans Affairs practitioners to prescribe controlled substances via telemedicine under specific conditions. The delay grants additional time to address any questions or issues and follows public feedback, with some comments favoring an immediate start and others requesting a postponement.

The Department of Justice, specifically the Drug Enforcement Administration (DEA), is requesting public feedback on a proposed information collection related to emergency medical services and controlled substances. This proposal aims to ensure compliance with the Controlled Substances Act by setting new recordkeeping standards for emergency medical services agencies. These standards involve maintaining records of controlled substances used by these agencies, which include details about administration, disposal, and delivery. The DEA encourages comments on the necessity, burden, and clarity of this information collection until January 13, 2025, as part of their efforts to secure approval for a three-year authorization under the Paperwork Reduction Act.

In January 2025, the Drug Enforcement Administration and the Department of Health and Human Services published new rules about expanding telemedicine practices. These rules were supposed to take effect on February 18, 2025, but have been delayed to March 21, 2025. This delay aligns with a Presidential order for a "Regulatory Freeze Pending Review," allowing more time for feedback on the rules. The rules allow certain medical professionals to prescribe medications via telemedicine, even without an initial in-person visit, under specific conditions. Public comments about this delay are encouraged, focusing on potential policy, legal, and factual issues.

The Department of Justice's Drug Enforcement Administration (DEA) is seeking public comments on its information collection proposal related to electronic prescriptions for controlled substances. This collection is critical for verifying practitioners' identities and managing their access to prescription systems securely. Affected groups include businesses, non-profits, and government entities, required to respond mandatorily. The DEA estimates that the total annual time burden for respondents will be 107,733 hours, with no additional cost burdens. Comments on the proposal will be accepted until March 3, 2025.